Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nature of Anifrolumab Impact on Vaccine-Emergent Immunity in Patients With Moderately to Severely Active Systemic Lupus Erythematosus: A Multi-Centre Open Label Parallel Group Trial:

Next Previous
Trial Profile

Nature of Anifrolumab Impact on Vaccine-Emergent Immunity in Patients With Moderately to Severely Active Systemic Lupus Erythematosus: A Multi-Centre Open Label Parallel Group Trial:

Status: Recruiting
Phase of Trial: Phase 0

Latest Information Update: 24 Mar 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Anifrolumab (Primary) ; Antimalarials; Azathioprine; Corticosteroids; Influenza virus vaccine; Methotrexate; Mycophenolate mofetil
  • Indications Systemic lupus erythematosus
  • Focus Pharmacodynamics
  • Acronyms NAIVE

Most Recent Events

  • 21 Mar 2023 Planned End Date changed from 31 Dec 2021 to 31 Dec 2024.
  • 21 Mar 2023 Planned primary completion date changed from 31 Dec 2021 to 31 Dec 2023.
  • 01 Feb 2021 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top